Tirzepatide activates brown fat in obese mice

Researchers led by Marion Peyrou at the University of Barcelona investigated whether tirzepatide affects adipose tissue independently of reduced food intake. In an experimental study, obese mice fed a high-fat diet received tirzepatide and were compared with untreated mice given the same amount of food. The team examined different fat deposits to distinguish drug-associated changes from those attributable to calorie restriction.

Tirzepatide activated brown adipose tissue, which uses energy rather than primarily storing it. Researchers associated this activation with increased capacity to burn metabolic energy and production of batokines, molecules released by brown fat that may influence metabolism. The source does not report animal numbers, treatment duration, dose, numerical effect sizes or statistical results.

The findings suggest a potential mechanism beyond appetite suppression for tirzepatide, a dual GIP and GLP-1 receptor agonist used for obesity and type 2 diabetes. However, this University of Barcelona–provided report describes animal research, not evidence of brown-fat activation in patients. Differences between mice and humans in metabolism, fat distribution and drug responses limit translation. Human studies are needed before this mechanism can inform treatment selection or explain clinical benefits.